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Each of the 8 members of the human herpesvirus family
identified to date has been associated, to varying degrees,
with congenital and perinatal transmission to the fetus
and newborn infant. The problem of prevention of mater-
nal-to-child transmission of herpesvirus infections is
complicated by a lack of understanding of correlates of
protective immunity for both the mother and the fetus.
Herpesviruses encode multiple immune evasion genes,
and establish lifelong, persistent infection in the host.
These issues render the design of protective vaccines
highly problematic.
In spite of these challenges, progress has been made in
recent years toward the development of new vaccines for
herpesviruses, in particular the viruses that pose the great-
est risk to the newborn – herpes simplex virus (HSV) and
cytomegalovirus (CMV). Recent strategies undergoing
evaluation in clinical trials include both the approach of
attenuated, live-virus vaccines as well as recombinant,
subunit vaccines that target immunodominant virally-
encoded proteins. A recombinant subunit vaccine against
genital HSV infection, based on the viral glycoprotein gD,
has demonstrated efficacy in placebo-controlled studies,
and merits further investigation. A benefit of immuniza-
tion against genital HSV for prevention of neonatal HSV
infection is inferred, although this endpoint may ulti-
mately be difficult to demonstrate in clinical trials.
Progress has also been made for immunization against
congenital infection with CMV. Given the neurodevelop-
mental injury associated with congenital CMV infection,
such a vaccine is a major public health priority. Recently,
subunit vaccination with the CMV glycoprotein, gB, has
demonstrated efficacy against acquisition of infection in a
phase II trial in young women. In a placebo-controlled
study, vaccination had a significant impact on the proba-
bility of a study participant remaining CMV seronegative
through the 42-month follow-up period. These data are
the first that demonstrate significant efficacy of a CMV
vaccine for prevention of infection, and will drive interest
in future gB vaccine studies using other expression tech-
nologies. Although these results are encouraging, ulti-
mately, several major issues must be resolved before CMV
vaccines can be optimized. First, the phenomena of re-
infection of CMV-immune hosts with new strains must be
understood, since non-primary CMV infections account
for the major disease burden of congenital CMV. Presum-
ably, vaccine design will need to account for the heteroge-
neity in clinical isolates that may account for most re-
infections. Secondly, the role of viral immune evasion
genes in abrogating host immunity must be clarified: a
better understanding of this process may, in turn, allow
design of optimized live, attenuated vaccines. Finally, the
role of immune responses that may potentially control
infection at mucosal surfaces needs to be elucidated, and
this knowledge may in turn facilitate development of
novel vaccines that block primary infection at mucosal
sites.
from Fifth Dominique Dormont International Conference. Mother-to-child transmitted viral diseases: from transmission to children care
Paris, France. 26–28 March 2009
Published: 22 July 2009
Retrovirology 2009, 6(Suppl 1):L2 doi:10.1186/1742-4690-6-S1-L2
<supplement> <title> <p>Fifth Dominique Dormont International Conference. Host-Pathogen Interactions in Chronic Infections</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-6-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S1/L2
© 2009 Schleiss; licensee BioMed Central Ltd. 
